Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:11:46 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:STTK - SHATTUCK LABS INC - http://www.smart-teksolutions.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
STTK - Q0.210.25·11.190.810.59+0.818.3381.53,7602,7969.82  10.64  9.7411.11  1.330118:42:12Apr 0915 min RT 2¢

Recent Trades - Last 10 of 2796
Time ETExPriceChangeVolume
18:42:12Q11.001.228
16:00:00Q10.590.81495
16:00:00Q10.590.8146
16:00:00Q10.590.81446
16:00:00Q10.590.811,200
16:00:00Q10.590.8143
16:00:00Q10.590.81267
16:00:00Q10.590.81399
16:00:00Q10.590.81100
16:00:00Q10.590.813

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-09 16:05U:STTKNews ReleaseShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-04-01 07:00U:STTKNews ReleaseShattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
2024-03-04 07:00U:STTKNews ReleaseShattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
2024-02-29 16:05U:STTKNews ReleaseShattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
2024-02-26 07:00U:STTKNews ReleaseShattuck Labs Announces Participation in Upcoming March Conferences
2024-02-14 05:06U:STTKNews ReleaseOno Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
2024-02-13 06:00U:STTKNews ReleaseShattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
2024-01-08 07:00U:STTKNews ReleaseShattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
2024-01-04 16:05U:STTKNews ReleaseShattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 08:00U:STTKNews ReleaseShattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
2023-12-13 06:00U:STTKNews ReleaseShattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat
2023-12-05 16:15U:STTKNews ReleaseShattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Da
2023-11-14 09:00U:STTKNews ReleaseShattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 06:00U:STTKNews ReleaseShattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2023-11-06 09:29U:STTKNews ReleaseShattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
2023-11-02 09:01U:STTKNews ReleaseShattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annua
2023-08-10 16:00U:STTKNews ReleaseShattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2023-05-25 17:15U:STTKNews ReleaseShattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
2023-05-09 16:00U:STTKNews ReleaseShattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights